Immatics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
407
- Stock Symbol
-
IMTX
- Investments
-
2
- Share Price
-
$6.39
- (As of Friday Closing)
Immatics General Information
Description
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Contact Information
Website
www.immatics.comCorporate Office
- Paul-Ehrlich-Strasse 15-19
- 72076 Tuebingen
- Germany
Corporate Office
- Paul-Ehrlich-Strasse 15-19
- 72076 Tuebingen
- Germany
Immatics Stock Performance
As of 13-Nov-2026, Immatics’s stock price is $6.39. Its current market cap is $973M with 152M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.39 | $6.50 | $6.08 - $12.41 | $973M | 152M | 899K | -$1.95 |
Immatics Financials Summary
As of 30-Sep-2026, Immatics has a trailing 12-month revenue of $50.5M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 904,057 | 921,474 | 334,258 | 521,418 |
| Revenue | 50,471 | 54,444 | 168,629 | 58,429 |
| EBITDA | (271,430) | (228,161) | 10,232 | (111,209) |
| Net Income | (269,581) | (221,593) | 16,467 | (102,417) |
| Total Assets | 641,540 | 660,532 | 724,390 | 563,715 |
| Total Debt | 15,820 | 18,365 | 16,860 | 17,025 |
Immatics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immatics Comparisons
Industry
Financing
Details
Immatics Competitors (27)
One of Immatics’s 27 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Innate Pharma | Formerly VC-backed | Marseille, France | ||||
| VBI Vaccines | Corporation | Cambridge, MA | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany |
Immatics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immatics Patents
Immatics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234246-A1 | Methods for determining a level of a therapeutic protein comprising an antigen binding site specifically binding to a peptide major histocompatibility complex (mhc) complex and anti-idiotypic antibodies binding thereto | Pending | 09-May-2025 | ||
| WO-2026202378-A2 | Engineered allogeneic immune cells | Pending | 27-Mar-2025 | ||
| WO-2026202378-A3 | Engineered allogeneic immune cells | Pending | 27-Mar-2025 | ||
| WO-2026150149-A1 | Bispecific tcer against a magea4- and a prame-derived peptide in combination with an immune checkpoint inhibitor for use in treating cancer | Pending | 13-Jan-2025 | ||
| WO-2026104504-A1 | Dosing of prame-specific tcer | Pending | 15-Nov-2024 | A61K39/001189 |
Immatics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immatics Investments & Acquisitions (2)
Immatics’s most recent deal was a PIPE with Topco Technologies for . The deal was made on 31-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Topco Technologies | 31-Jul-2020 | PIPE | Specialty Chemicals | ||
| ARYA Sciences Acquisition | 01-Jul-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Immatics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Immatics FAQs
-
When was Immatics founded?
Immatics was founded in 2000.
-
Where is Immatics headquartered?
Immatics is headquartered in Tuebingen, Germany.
-
What is the size of Immatics?
Immatics has 407 total employees.
-
What industry is Immatics in?
Immatics’s primary industry is Drug Discovery.
-
Is Immatics a private or public company?
Immatics is a Public company.
-
What is Immatics’s stock symbol?
The ticker symbol for Immatics is IMTX.
-
What is the current stock price of Immatics?
As of 13-Nov-2026 the stock price of Immatics is $6.39.
-
What is the current market cap of Immatics?
The current market capitalization of Immatics is $973M.
-
What is Immatics’s current revenue?
The trailing twelve month revenue for Immatics is $50.5M.
-
Who are Immatics’s competitors?
Agenus, Innate Pharma, VBI Vaccines, Roche, and Evotec are some of the 27 competitors of Immatics.
-
What is Immatics’s annual earnings per share (EPS)?
Immatics’s EPS for 12 months was -$1.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
